On July 29, 2020, the board of directors of ADC Therapeutics SA (the “Company”) amended the company’s organizational regulations to create the science and technology committee of the board of directors. The amendment is effective on July 29, 2020. The science and technology committee, which consists of Victor Sandor (chair), Peter B. Corr, Peter Hug and Tyrell J. Rivers, is responsible for reviewing and making recommendations to the board of directors regarding the Company’s research and development activities, strategies, programs and objectives. The members of the science and technology committee and its chair are appointed by the Company’s board of directors. The science and technology committee has the responsibility to, among other things: review and make recommendations to the Board of Directors regarding the Company's preclinical and clinical research and development activities, including related CMC activities; review and make recommendations to the Board of Directors regarding preclinical and clinical research and development strategies; review and make recommendations to the Board of Directors regarding the Company's preclinical and clinical research guidelines; provide strategic advice to the Board of Directors regarding emerging science and technology issues and trends; examine periodically the Company's measures to keep the research and development personnel motivated, productive and entrepreneurially oriented; Through regular review and consultation with the CEO and his team that appropriate Research and Development objectives are in place that are aligned with the company’s overall Research and Development strategy, and that progress against these objectives is being appropriately assessed; and ensure that appropriate market potential assessments are being conducted.